Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b

P. Bramanti, E. Sessa, C. Rifici, G. D'Aleo, D. Floridia, P. Di Bella, F. Lublin

Research output: Contribution to journalArticle

Abstract

Spasticity is a disabling symptom of MS that is enhanced during interferon beta-1b (IFNβ-1b) treatment. Nineteen patients with primary progressive MS were treated with IFNβ-1b; an additional 19 patients did not receive this treatment. Thirteen of the 19 patients treated with IFNβ-1b had increased spasticity requiring increased antispasticity drug administration. This observation suggests that further studies are needed before interferons can be so widely used in primary progressive MS patients.

Original languageEnglish
Pages (from-to)1720-1723
Number of pages4
JournalNeurology
Volume51
Issue number6
Publication statusPublished - 1998

Fingerprint

Interferons
Interferon beta-1b
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b. / Bramanti, P.; Sessa, E.; Rifici, C.; D'Aleo, G.; Floridia, D.; Di Bella, P.; Lublin, F.

In: Neurology, Vol. 51, No. 6, 1998, p. 1720-1723.

Research output: Contribution to journalArticle

@article{36a508e8651840c3a723882cc8c3beca,
title = "Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b",
abstract = "Spasticity is a disabling symptom of MS that is enhanced during interferon beta-1b (IFNβ-1b) treatment. Nineteen patients with primary progressive MS were treated with IFNβ-1b; an additional 19 patients did not receive this treatment. Thirteen of the 19 patients treated with IFNβ-1b had increased spasticity requiring increased antispasticity drug administration. This observation suggests that further studies are needed before interferons can be so widely used in primary progressive MS patients.",
author = "P. Bramanti and E. Sessa and C. Rifici and G. D'Aleo and D. Floridia and {Di Bella}, P. and F. Lublin",
year = "1998",
language = "English",
volume = "51",
pages = "1720--1723",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b

AU - Bramanti, P.

AU - Sessa, E.

AU - Rifici, C.

AU - D'Aleo, G.

AU - Floridia, D.

AU - Di Bella, P.

AU - Lublin, F.

PY - 1998

Y1 - 1998

N2 - Spasticity is a disabling symptom of MS that is enhanced during interferon beta-1b (IFNβ-1b) treatment. Nineteen patients with primary progressive MS were treated with IFNβ-1b; an additional 19 patients did not receive this treatment. Thirteen of the 19 patients treated with IFNβ-1b had increased spasticity requiring increased antispasticity drug administration. This observation suggests that further studies are needed before interferons can be so widely used in primary progressive MS patients.

AB - Spasticity is a disabling symptom of MS that is enhanced during interferon beta-1b (IFNβ-1b) treatment. Nineteen patients with primary progressive MS were treated with IFNβ-1b; an additional 19 patients did not receive this treatment. Thirteen of the 19 patients treated with IFNβ-1b had increased spasticity requiring increased antispasticity drug administration. This observation suggests that further studies are needed before interferons can be so widely used in primary progressive MS patients.

UR - http://www.scopus.com/inward/record.url?scp=0031676732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031676732&partnerID=8YFLogxK

M3 - Article

C2 - 9855531

AN - SCOPUS:0031676732

VL - 51

SP - 1720

EP - 1723

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 6

ER -